Metabolomics

, 12:118 | Cite as

Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM)

Original Article
First Online:
Received:
Accepted:
Part of the following topical collections:
  1. Recent advances in Pharmacometabolomics: enabling tools for precision medicine

Abstract

Objectives

In this review we compare the advantages and disadvantages of different model biological systems for determining the metabolic functions of cells in complex environments, how they may change in different disease states, and respond to therapeutic interventions.

Introduction

All preclinical drug-testing models have advantages and drawbacks. We compare and contrast established cell, organoid and animal models with ex vivo organ or tissue culture and in vivo human experiments in the context of metabolic readout of drug efficacy. As metabolism reports directly on the biochemical state of cells and tissues, it can be very sensitive to drugs and/or other environmental changes. This is especially so when metabolic activities are probed by stable isotope tracing methods, which can also provide detailed mechanistic information on drug action. We have developed and been applying Stable Isotope-Resolved Metabolomics to examine metabolic reprogramming of human lung cancer cells in monoculture, in mouse xenograft/explant models, and in lung cancer patients in situ (Lane et al. in Omics 15:173–182, 2011; Fan et al. in Metabolomics 7(2):257–269, 2011a, in Pharmacol Ther 133:366–391, 2012a, in Metabolomics 8(3):517–527, b; Xie et al. in Cell Metab 19:795–809, 2014; Ren et al. in Sci Rep 4:5414, 2014; Sellers et al. in J Clin Investig 125(2):687–698, 2015). We are able to determine the influence of the tumor microenvironment using these models. We have now extended the range of models to fresh human tissue slices, similar to those originally described by Warburg (Biochem Z 142:317–333, 1923), which retain the native tissue architecture and heterogeneity with a paired benign versus cancer design under defined cell culture conditions. This platform offers an unprecedented human tissue model for preclinical studies on metabolic reprogramming of human cancer cells in their tissue context, and response to drug treatment (Xie et al. 2014). As the microenvironment of the target human tissue is retained and individual patient’s response to drugs is obtained, this platform promises to transcend current limitations of drug selection for clinical trials or treatments

Conclusions

Development of ex vivo human tissue and animal models with humanized organs including bone marrow and liver show considerable promise for analyzing drug responses that are more relevant to humans. Similarly using stable isotope tracer methods with these improved models in advanced stages of the drug development pipeline, in conjunction with tissue biopsy is expected significantly to reduce the high failure rate of experimental drugs in Phase II and III clinical trials.

Keywords

SIRM Cell culture PDX models Tissue slices Metabolism 

Abbreviations

IRB

Institutional Review Board

PDX

Patient derived xenograft

(m)SIRM

(multiplexed) Stable Isotope-Resolved Metabolomics

This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported in part by NIH P01CA163223-01A1, 1U24DK097215-01A1, 1R01ES022191-01 and 1R21ES025669-01.

Compliance with ethical standards

Conflict of interest

Andrew Lane, Richard Higashi and Teresa Fan declare no conflicts of interest.

Informed consent

Human tissues reported in Fig. 3 were obtained with informed consent under an IRB-approved protocol at the University of Kentucky.

References

  1. Adams, C. P., & Brantner, V. V. (2010). Spending on new drug development. Health Economics, 19(2), 130–141.PubMedCrossRefGoogle Scholar
  2. Ahuja, D., Sáenz-Robles, M. T., & Pipas, J. M. (2005). SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene, 24, 7729–7745.PubMedCrossRefGoogle Scholar
  3. Amiri-Kordestani, L., & Fojo, T. (2012). Why do phase III clinical trials in oncology fail so often? JNCI, 104, 568–569.PubMedCrossRefGoogle Scholar
  4. Aparicio, S., Hidalgo, M., & Kung, A. L. (2015). Examining the utility of patient-derived xenograft mouse models. Nature Reviews Cancer, 15, 311–316.PubMedCrossRefGoogle Scholar
  5. Arinze, I. J., & Hanson, R. W. (1980). Compartmentation and its role in metabolic regulation. In R. M. Cohn, R. H. Herman, & P. D. McNamara (Eds.), Principles of metabolic control in mammalian systems (pp. 495–534). US: Springer.CrossRefGoogle Scholar
  6. Arita, M. (2004). The metabolic world of Escherichia coli is not small. Proceedings of the National Academy of Sciences of the United States of America, 101(6), 1543–1547.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Arrowsmith, J. (2011). Biobusiness briefs: Trial watch: Phase II failures: 2008–2010. Nature Reviews Drug Discovery, 10, 328–329.PubMedCrossRefGoogle Scholar
  8. Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., et al. (2007). Robust expansion of human hepatocytes in Fah(−/−)/Rag2(−/−)/Il2rg(−/−) mice. Nature Biotechnology, 25(8), 903–910.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Beloribi-Djefaflia, S., Siret, C., & Lombardo, D. (2015). Exosomal lipids induce human pancreatic tumoral MiaPaCa-2 cells resistance through the CXCR4-SDF-1alpha signaling axis. Oncoscience, 2(1), 15–30.PubMedGoogle Scholar
  10. Belteki, G., Haigh, J., Kabacs, N., Haigh, K., Sison, K., Costantini, F., et al. (2005). Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction. Nucleic Acids Research, 33, e51.PubMedPubMedCentralCrossRefGoogle Scholar
  11. Berndt, W. O. (1976). Use of tissue slice technique for evaluation of renal transport processes. Environmental Health Perspectives, 15, 73–88.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Bility, M. T., Zhang, L., Washburn, M. L., Curtis, T. A., Kovalev, G. I., & Su, L. (2012). Generation of a humanized mouse model with both human immune system and liver cells to model hepatitis C virus infection and liver immunopathogenesis. Nature Protocols, 7(9), 1608–1617. doi: 10.1038/nprot.2012.083.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Bissell, M. J., Rizki, A., & Mian, I. S. (2003). Tissue architecture: The ultimate regulator of breast epithelial function. Current Opinion in Cell Biology, 15(6), 753–762.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Blacker, T. S., Mann, Z. F., Gale, J. E., Ziegler, M., Bain, A. J., Szabadkai, G., et al. (2014). Separating NADH and NADPH fluorescence in live cells and tissues using FLIM. Nature Communications, 5, 3936.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Bonuccelli, G., Whitaker-Menezes, D., Castello-Cros, R., Pavlides, S., Pestell, R. G., Fatatis, A., et al. (2010). The reverse Warburg effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle, 9(10), 1960–1971.PubMedCrossRefGoogle Scholar
  16. Boumezbeur, F., Petersen, K. F., Cline, G. W., Mason, G. F., Behar, K. L., Shulman, G. I., et al. (2010). The contribution of blood lactate to brain energy metabolism in humans measured by dynamic C-13 nuclear magnetic resonance spectroscopy. Journal of Neuroscience, 30(42), 13983–13991.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Bousamra, M., Day, J., Fan, T. W.-M., Higashi, R. M., Kloecker, G., Lane, A. N., et al. (2012). Clinical aspects of metabolomics. In The handbook of metabolomics. (Vol. 17, Vol. Methods in Pharmacology and Toxicology). Totoya: Humana.Google Scholar
  18. Brehm, M. A., Shultz, L. D., & Greiner, D. L. (2010). Humanized mouse models to study human diseases. Current opinion in Endocrinology, Diabetes, and Obesity, 17(2), 120–125.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Brehm, M. A., Shultz, L. D., Luban, J., & Greiner, D. L. (2013). Overcoming current limitations in humanized mouse research. Journal of Infectious Diseases, 208, S125–S130.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Buescher, J. M., Antoniewicz, M. R., Boros, L. G., Burgess, S. C., Brunengraber, H., Clish, C. B., et al. (2015). A roadmap for interpreting (13)C metabolite labeling patterns from cells. Current Opinion in Biotechnology, 34, 189–201.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Caneba, C. A., Yang, L., Baddour, J., Curtis, R., Win, J., Hartig, S., et al. (2014). Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells. Cell Death and Disease, 5, e1302.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Cascante, M., Franco, R., & Canela, E. I. (1989). Use of implicit methods from general sensitivity theory to develop a systematic-approach to metabolic control. 2. Complex-systems. Mathematical Biosciences, 94(2), 289–309.PubMedCrossRefGoogle Scholar
  23. Cascante, M., Selivanov, V., & Ramos-Montoya, A. (2012). Application of traceer-based metabolomics and flux analysis in targteted cancer drug design. In T. W.-M. Fan, A. N. Lane, & R. M. Higashi (Eds.), The handbook of metabolomics (pp. 299–320, Methods in Pahrmacology and Toxicology). New York: Springer.Google Scholar
  24. Cassidy, J. W., Caldas, C., & Bruna, A. (2015). Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Research, 75, 2963–2968.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Chatham, J. C., & Seymour, A.-M. L. (2002). Cardiac carbohydrate metabolism in Zucker diabetic fatty rats. Cardiovascular Research, 55(1), 104–112.PubMedCrossRefGoogle Scholar
  26. Cheung, V. G., Conlin, L. K., Weber, T. M., Arcaro, M., Jen, K.-Y., Morley, M., et al. (2003). Natural variation in human gene expression assessed in lymphoblastoid cells. Nature Genetics, 33, 422–425.PubMedCrossRefGoogle Scholar
  27. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., et al. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 325, 834–840.PubMedCrossRefGoogle Scholar
  28. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., & Cantley, L. C. (2008). Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature, 452, 181–186.PubMedCrossRefGoogle Scholar
  29. Covassin, L., Jangalwe, S., Jouvet, N., Laning, J., Burzenski, L., Shultz, L. D., et al. (2013). Human immune system development and survival of non-obese diabetic (NOD)-scid IL2r gamma(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells. Clinical and Experimental Immunology, 174, 372–388.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Damhofer, H., Ebbing, E. A., Steins, A., Welling, L., Tol, J. A., Krishnadath, K. K., et al. (2015). Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. Journal of Translational Medicine, 13, 115.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., et al. (2016). Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metabolism, 23, 517–528.PubMedCrossRefGoogle Scholar
  32. de Graaf, R. A., Rothman, D. L., & Behar, K. L. (2011). State of the art direct C-13 and indirect H-1- C-13 NMR spectroscopy in vivo. A practical guide. NMR in Biomedicine, 24(8), 958–972.PubMedPubMedCentralCrossRefGoogle Scholar
  33. deGraaf, I. A. M., Olinga, P., deJager, M. H., Merema, M. T., deKanter, R., van de Kerkhof, E. G., et al. (2010). Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nature Protocols, 5, 1540–1551.CrossRefGoogle Scholar
  34. Delitto, D., Perez, C., Han, S., Gonzalo, D. H., Pham, K., Knowlton, A. E., et al. (2015). Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. Cancer Immunology, Immunotherapy, 64(12), 1553–1563.PubMedCrossRefGoogle Scholar
  35. Dixit, P., Jain, D. K., & Dumbwani, J. (2012). Standardization of an ex vivo method for determination of intestinal permeability of drugs using everted rat intestine apparatus. Journal of Pharmacological and Toxicological Methods, 65, 13–17.PubMedCrossRefGoogle Scholar
  36. Fan, T. W.-M., Kucia, M., Jankowski, K., Higashi, R. M., Rataczjak, M. Z., Rataczjak, J., et al. (2008). Proliferating Rhabdomyosarcoma cells shows an energy producing anabolic metabolic phenotype compared with Primary Myocytes. Molecular Cancer, 7, 79.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Fan, T. W.-M., & Lane, A. N. (2016). Applications of NMR spectroscopy to systems biochemistry. Progress NMR Spectroscopy, 92, 18–53.CrossRefGoogle Scholar
  38. Fan, T. W.-M., Lane, A. N., & Higashi, R. M. (2016a). Stable isotope resolved metabolomics studies in ex vivo tissue slices. Bio-protocol, 6, e1730.PubMedPubMedCentralGoogle Scholar
  39. Fan, T. W., Lane, A. N., Higashi, R. M., Farag, M. A., Gao, H., Bousamra, M., et al. (2009). Altered regulation of metabolic pathways in human lung cancer discerned by 13C stable isotope-resolved metabolomics (SIRM). Molecular Cancer, 8, 41.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Fan, T. W., Lane, A. N., Higashi, R. M., & Yan, J. (2011a). Stable isotope resolved metabolomics of lung cancer in a SCID mouse model. Metabolomics, 7(2), 257–269.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Fan, T. W.-M., Lane, A. N., Higashi, R. M., & Yan, J. (2011b). Stable isotope resolved metabolomics of lung cancer in a SCID mouse model. Metabolomics, 7, 257–269.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Fan, T. W.-M., Lorkiewicz, P., Sellers, K., Moseley, H. N. B., Higashi, R. M., & Lane, A. N. (2012a). Stable isotope-resolved metabolomics and applications to drug development. Pharmacology & Therapeutics, 133, 366–391.CrossRefGoogle Scholar
  43. Fan, T. W.-M., Tan, J. L., McKinney, M. M., & Lane, A. N. (2012b). Stable isotope resolved metabolomics analysis of ribonucleotide and RNA metabolism in human lung cancer cells. Metabolomics, 8(3), 517–527.PubMedCrossRefGoogle Scholar
  44. Fan, T. W.-M., Warmoes, M. O., Sun, Q., Song, H., T, Turchan-Cholewo, J., Martin, J. T., et al. (2016b). Distinctly perturbed metabolic networks underlie differential tumor tissue damages induced by immune modulator β-glucan in a two-case ex vivo non-small cell lung cancer study. CSH Molecular Case Studies Journal. doi: 10.1101/mcs.a000893.
  45. Feenstra, J., Grobbee, D. E., Remme, W. J., & Stricker, B. H. C. (1999). Drug-induced heart failure. Journal of the American College of Cardiology, 33, 1152–1162.PubMedCrossRefGoogle Scholar
  46. Fell, D. (1997). Understanding the control of metabolism (Frontiers in metabolism). London: Portland Press.Google Scholar
  47. Fogh, J. (Ed.). (1982). The nude mouse in experimental and clinical research. Cambridge: Academic Press.Google Scholar
  48. Freeman, B. A., & Oneil, J. J. (1984). Tissue-slices in the study of lung metabolism and toxicology. Environmental Health Perspectives, 56, 51–60.PubMedPubMedCentralCrossRefGoogle Scholar
  49. Gadian, D. G. (1986). In vivo NMR. In Supramolecular structure and function. Proceedings in life sciences (pp. 93–103).Google Scholar
  50. Gadian, D. G. (1995). NMR and its applications to living systems (2nd ed.). Oxford: Oxford University Press.Google Scholar
  51. Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015). Translational value of mouse models in oncology drug development. Nature Medicine, 21, 431–439.PubMedCrossRefGoogle Scholar
  52. Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezene, P., et al. (2013). Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 110(10), 3919–3924.PubMedPubMedCentralCrossRefGoogle Scholar
  53. Hahne, H., Gholami, A. M., & Kuster, B. (2012). Discovery of O-GlcNAc-modified proteins in published large-scale proteome data. Molecular and Cellular Proteomics, 11(10), 843–850.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.PubMedCrossRefGoogle Scholar
  55. Hasegawa, M., Kawai, K., Mitsui, T., Taniguchi, K., Monnai, M., Wakui, M., et al. (2011). The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochemical and Biophysical Research Communications, 405(3), 405–410.PubMedPubMedCentralCrossRefGoogle Scholar
  56. Hensley, C. T., Faubert, B., Yuan, Q., Lev-Cohain, N., Jin, E., Kim, J., et al. (2016). Metabolic heterogeneity in human lung tumors. Cell, 164, 681–694.PubMedCrossRefGoogle Scholar
  57. Herzenberg, J. R. (2009). Renal toxicity of therapeutic drugs. Journal of Clinical Pathology, 62, 505–515.PubMedCrossRefGoogle Scholar
  58. Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., et al. (2011). A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular Cancer Therapeutics, 10(8), 1311–1316.PubMedPubMedCentralCrossRefGoogle Scholar
  59. Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., et al. (2016). Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell, 162(6), 1217–1228.CrossRefGoogle Scholar
  60. Hornbeck, P. V. (2015). PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Research, 43(D1), D512–D520.PubMedCrossRefGoogle Scholar
  61. Hougardy, B. M. T., Reesink-Peters, N., van den Heuvel, F. A. J., ten Hoor, K. A., Hollema, H., de Vries, E. G. E., et al. (2008). A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. International Journal of Cancer, 123(6), 1457–1465.PubMedCrossRefGoogle Scholar
  62. Hu, S., Yoshihara, H. A. I., Bok, R., Zhou, J., Zhu, M. H., Kurhanewicz, J., et al. (2012). Use of hyperpolarized 1-C-13 pyruvate and 2-C-13 pyruvate to probe the effects of the anticancer agent dichloroacetate on mitochondrial metabolism in vivo in the normal rat. Magnetic Resonance Imaging, 30(10), 1367–1372.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Huang, K. Y., Su, M. G., Kao, H. J., Hsieh, Y. C., Jhong, J. H., Cheng, K. H., et al. (2016). dbPTM 2016: 10-year anniversary of a resource for post-translational modification of proteins. Nucleic Acids Research, 44(D1), D435–D446.PubMedCrossRefGoogle Scholar
  64. Hyder, F., Fulbright, R. K., Shulman, R. G., & Rothman, D. L. (2013). Glutamatergic function in the resting awake human brain is supported by uniformly high oxidative energy. Journal of Cerebral Blood Flow and Metabolism, 33(3), 339–347.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Ishida, Y., Yamasaki, C., Yanagi, A., Yoshizane, Y., Fujikawa, K., Watashi, K., et al. (2015). Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice. American Journal of Pathology, 185(5), 1275–1285.PubMedCrossRefGoogle Scholar
  66. Jack, J., Rotroff, D., & Motsinger-Reif, A. (2014). Lymphoblastoid cell lines models of drug response: Successes and lessons from this pharmacogenomic model. Current Molecular Medicine, 14(7), 833–840.PubMedPubMedCentralCrossRefGoogle Scholar
  67. Jitrapakdee, S., St Maurice, M., Rayment, I., Cleland, W. W., Wallace, J. C., & Attwood, P. V. (2008). Structure, mechanism and regulation of pyruvate carboxylase. Biochemical Journal, 413, 369–387.PubMedPubMedCentralCrossRefGoogle Scholar
  68. Keshari, K. R., Kurhanewicz, J., Bok, R., Larson, P. E. Z., Vigneron, D. B., & Wilson, D. M. (2011). Hyperpolarized C-13 dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. Proceedings of the National Academy of Sciences of the United States of America, 108(46), 18606–18611.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Keshari, K. R., Sriram, R., Van Criekinge, M., Wilson, D. M., Wang, Z. J., Vigneron, D. B., et al. (2013). Metabolic reprogramming and validation of hyperpolarized C-13 lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate, 73(11), 1171–1181.PubMedPubMedCentralCrossRefGoogle Scholar
  70. Kim, J. W., & Dang, C. V. (2005). Multifaceted roles of glycolytic enzymes. Trends in Biochemical Sciences, 30(3), 142–150.PubMedCrossRefGoogle Scholar
  71. Kirby, T. O., Rivera, A., Rein, D., Wang, M., Ulasov, I., Breidenbach, M., et al. (2004). A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clinical Cancer Research, 10(24), 8697–8703.PubMedCrossRefGoogle Scholar
  72. Kopetz, S., Lemos, R., & Powis, G. (2012). The promise of patient-derived xenografts: The best laid plans of mice and men. Clinical Cancer Research, 18, 5160–5162.PubMedPubMedCentralCrossRefGoogle Scholar
  73. Lane, A. N., Fan, T. W.-M., Bousamra, M, I. I., Higashi, R. M., Yan, J., & Miller, D. M. (2011). Clinical applications of stable isotope-resolved metabolomics (SIRM) in non-small cell lung cancer. OMICS: A Journal of Integrative Biology, 15, 173–182.PubMedCrossRefGoogle Scholar
  74. Lane, A. N., Fan, T. W., & Higashi, R. M. (2008a). Isotopomer-based metabolomic analysis by NMR and mass spectrometry. Biophysical Tools for Biologists., 84, 541–588.Google Scholar
  75. Lane, A. N., Fan, T. W.-M., Higashi, R. M., Deleeuw, L., & Yang, T. H. (2008). Stable isotope tracing in metabolic pathways. Paper presented at the modelling complex biological systems in the context of the genome, Lille.Google Scholar
  76. Lane, A. N., Fan, T. W.-M., Xie, X., Moseley, H. N., & Higashi, R. M. (2009). Stable isotope analysis of lipid biosynthesis by high resolution mass spectrometry and NMR. Analytica Chimica Acta, 651, 201–208.PubMedPubMedCentralCrossRefGoogle Scholar
  77. Lane, A. N., Yan, J., & Fan, T. W.-M. (2015). 13C tracer studies of metabolism in mouse tumor xenografts. Bio-protocol, 5, e1650.Google Scholar
  78. Ledford, H. (2015). CRISPR, the disruptor. Nature, 522, 20–24.PubMedCrossRefGoogle Scholar
  79. Lee, K. M., Choi, K. H., & Ouellette, M. M. (2004). Use of exogenous hTERT to immortalize primary human cells. Cytotechnology, 45, 33–38.PubMedPubMedCentralCrossRefGoogle Scholar
  80. Lee, J., Cuddihy, M. J., & Kotov, N. A. (2008). Three-dimensional cell culture matrices: State of the art. Tissue Engineering Part B: Reviews, 14(1), 61–86.CrossRefGoogle Scholar
  81. Lee, G. Y., Kenny, P. A., Lee, E. H., & Bissell, M. J. (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nature Methods, 4, 359–365.PubMedPubMedCentralCrossRefGoogle Scholar
  82. Leithner, K., Wohlkoenig, C., Stacher, E., Lindenmann, J., Hofmann, N. A., Galle, B., et al. (2014). Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model-role of tumor stroma cells. BMC Cancer, 14, 40.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Lincet, J., & Icard, P. (2015). How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions? Oncogene, 34, 3751–3759.PubMedCrossRefGoogle Scholar
  84. Maher, E. A., Marin-Valencia, I., Bachoo, R. M., Mashimo, T., Raisanen, J., Hatanpaa, K. J., et al. (2012). Metabolism of U-13C glucose in human brain tumors in vivo. NMR in Biomedicine, 25(11), 1234–1244.PubMedPubMedCentralCrossRefGoogle Scholar
  85. Marin, R., Perez, J. C. G., Ralph, S. J., Rodriguez-Enriquez, S., & Moreno-Sanchez, R. (2009). HIF-1α modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Reviews in Medicinal Chemistry, 9, 1084–1101.CrossRefGoogle Scholar
  86. Martinez-Garcia, R., Juan, D., Rausell, A., Munoz, M., Banos, N., Menendez, C., et al. (2014). Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Medicine, 6, 27.PubMedPubMedCentralCrossRefGoogle Scholar
  87. Mason, G. F., Petersen, K. F., de Graaf, R. A., Kanamatsu, T., Otsuki, T., & Rothman, D. L. (2002). A comparison of C-13 NMR measurements of the rates of glutamine synthesis and the tricarboxylic acid cycle during oral and intravenous administration of 1-C-13 glucose. Brain Research Protocols, 10(3), 181–190.CrossRefGoogle Scholar
  88. Mathupala, S. P., Ko, Y. H., & Pedersen, P. L. (2010). The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochimica et Biophysica Acta, 1797, 1225–1230.PubMedPubMedCentralCrossRefGoogle Scholar
  89. Maykel, J., Liu, J. H., Li, H., Shultz, L. D., Greiner, D. L., & Houghton, J. (2014). NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl): a model for stromal cell-tumor cell interaction for human colon cancer. Digestive Diseases and Sciences, 59, 1169–1179.PubMedPubMedCentralCrossRefGoogle Scholar
  90. McCracken, K. W., Cata, E. M., Crawford, C. M., Sinagoga, K. L., Schumacher, M., Rockich, B. E., et al. (2014). Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature, 516(7531), 400–404.PubMedPubMedCentralCrossRefGoogle Scholar
  91. Mestas, J., & Hughes, C. C. W. (2004). Of mice and not men: Differences between mouse and human immunology. Journal of Immunology, 172, 2731–2738.CrossRefGoogle Scholar
  92. Minárik, P., Tomásková, N., Kollárová, M., & Antalik, M. (2002). Malate dehydrogenases–structure and function. General Physiology and Biophysics, 21, 257–265.PubMedGoogle Scholar
  93. Mitchell, J. M., Fan, T. W.-M., Lane, A. N., & Moseley, H. N. B. (2014). Development and in silico evaluation of large-scale metabolite identification methods using functional group detection for metabolomics. Frontiers in Genetics, 5, 273.Google Scholar
  94. Moore, C. B., Guthrie, E. H., Huang, M. T.-H., & Taxman, D. J. (2010). Short hairpin RNA (shRNA): Design, delivery, and assessment of gene knockdown. Methods in Molecular Biology, 629, 141–158.PubMedPubMedCentralGoogle Scholar
  95. Muruganandan, S., & Sinal, C. J. (2008). Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clinical Pharmacology and Therapeutics, 83, 818–828.PubMedCrossRefGoogle Scholar
  96. Natoli, M., Leoni, B. D., D’Agnano, I., Zucco, F., & Felsani, A. (2012). Good Caco-2 cell culture practices. Toxicology in Vitro, 26, 1243–1246.PubMedCrossRefGoogle Scholar
  97. Neitzel, H. (1986). A routine method for the establishment of permanent growing lymphoblastoid cell lines. Human Genetics, 73, 320–326.PubMedCrossRefGoogle Scholar
  98. Nelson, S. J., Kurhanewicz, J., Vigneron, D. B., Larson, P. E. Z., Harzstark, A. L., Ferrone, M., et al. (2013). Metabolic imaging of patients with prostate cancer using hyperpolarized 1-C-13 pyruvate. Science Translational Medicine, 5, 198.CrossRefGoogle Scholar
  99. Niu, N. F., & Wang, L. W. (2015). In vitro human cell line models to predict clinical response to anticancer drugs. Pharmacogenomics, 16(3), 273–285.PubMedPubMedCentralCrossRefGoogle Scholar
  100. Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H., et al. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of Internal Medicine, 137, 947–954.PubMedCrossRefGoogle Scholar
  101. Pajic, A., Spitkovsky, D., Christoph, B., Kempkes, B., Schuhmacher, M., Staege, M. S., et al. (2000). Cell cycle activation by c-myc in a Burkitt lymphoma model cell line. International Journal of Cancer, 87, 787–793.PubMedCrossRefGoogle Scholar
  102. Patel, A. B., de Graaf, R. A., Mason, G. F., Rothman, D. L., Shulman, R. G., & Behar, K. L. (2005). The contribution of GABA to glutamate/glutamine cycling and energy metabolism in the rat cortex in vivo. Proceedings of the National Academy of Sciences of the United States of America, 102(15), 5588–5593.PubMedPubMedCentralCrossRefGoogle Scholar
  103. Pawlik, T. M., Souba, W. W., Sweeney, T. J., & Bode, B. P. (2000). Amino acid uptake and regulation in multicellular hepatoma spheroids. Journal of Surgical Research, 91(1), 15–25.PubMedCrossRefGoogle Scholar
  104. Pfeiffer, T., Soyer, O. S., & Bonhoeffer, S. (2005). The evolution of connectivity in metabolic networks. PLoS Biology, 3, e228.PubMedPubMedCentralCrossRefGoogle Scholar
  105. Poulo, J. M., Elston, T., Lane, A. N., Macdonald, J. M., & Cascante, M. (2012). Introduction to metabolic control analysis (MCA). In T. W.-M. Fan, R. M. Higashi, & A. N. Lane (Eds.), Handbook of metabolomics. New York: Humana Press.Google Scholar
  106. Ravi, M., Paramesh, V., Kaviya, S. R., Anuradha, E., & Paul Solomon, F. D. P. (2014). 3D cell culture systems: advantages and applications. Journal of Cellular Physiology, 230, 16–26.CrossRefGoogle Scholar
  107. Ren, J. G., Seth, P., Clish, C. B., Lorkiewicz, P. K., Higashi, R. M., Lane, A. N., et al. (2014). Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling. Scientific Reports, 4, 5414.PubMedPubMedCentralGoogle Scholar
  108. Richmond, A., & Su, Y. (2008). Mouse xenograft models vs GEM models for human cancer therapeutics. Disease Models & Mechanisms, 1(2–3), 78–82.CrossRefGoogle Scholar
  109. Roberts, J. K. M., Lane, A. N., Clark, R. A., & Nieman, R. H. (1985). Relationships between the rate of synthesis of ATP and the concentrations of reactants and products of ATP hydrolysis in maize root-tips, determined by P-31 nuclear magnetic-resonance. Archives of Biochemistry and Biophysics, 240(2), 712–722.PubMedCrossRefGoogle Scholar
  110. Rose, J., Martin, C., MacDonald, T., & Ellis, C. (2006). High-resolution intravital NADH fluorescence microscopy allows measurements of tissue bioenergetics in rat ileal mucosa. Microcirculation, 13(1), 41–47.PubMedCrossRefGoogle Scholar
  111. Ruprecht, B., & Lemeer, S. (2014). Proteomic analysis of phosphorylation in cancer. Expert Review of Proteomics, 11(3), 259–267.PubMedCrossRefGoogle Scholar
  112. Sander, J. D., & Joung, J. K. (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnology, 32, 347–355.PubMedPubMedCentralCrossRefGoogle Scholar
  113. Saunders, T. (2011). Inducible transgenic mouse models. Methods in Molecular Biology, 693, 103–115.PubMedCrossRefGoogle Scholar
  114. Savageau, M. A., Voit, E. O., & Irvine, D. H. (1987a). Biochemical systems-theory and metabolic control-theory. 1. Fundamental similarities and differences. Mathematical Biosciences, 86(2), 127–145.CrossRefGoogle Scholar
  115. Savageau, M. A., Voit, E. O., & Irvine, D. H. (1987b). Biochemical systems-theory and metabolic control-theory. 2. The role of summation and connectivity relationships. Mathematical Biosciences, 86(2), 147–169.CrossRefGoogle Scholar
  116. Scaduto, R. C., & Davis, E. J. (1985). Serine synthesis by an isolated perfused rat kidney preparation. Biochemical Journal, 230, 303–311.PubMedPubMedCentralCrossRefGoogle Scholar
  117. Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G. (2013). Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Frontiers in Oncology, 3, 295.PubMedPubMedCentralCrossRefGoogle Scholar
  118. Sellers, K., Fox, M. P., Bousamra, M, I. I., Slone, S. P., Higashi, R. M., Miller, D. M., et al. (2015). Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. Journal of Clinical Investigation, 125(2), 687–698.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Shultz, L. D., Ishikawa, F., & Greiner, D. L. (2007). Humanized mice in translational biomedical research. Nature Reviews Immunology, 7, 118–130.PubMedCrossRefGoogle Scholar
  120. Siolas, D., & Hannon, G. J. (2013). Patient derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Research, 73, 5315–5319.PubMedPubMedCentralCrossRefGoogle Scholar
  121. Sonveaux, P., Vegran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., et al. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of Clinical Investigation, 118(12), 3930–3942.PubMedPubMedCentralGoogle Scholar
  122. Spence, J. R., Mayhew, C. N., Rankin, S. A., Kuhar, M. F., Vallance, J. E., Tolle, K., et al. (2011). Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature, 470(7332), 105–109.PubMedCrossRefGoogle Scholar
  123. Sriram, G., Martinez, J. A., McCabe, E. R. B., Liao, J. C., & Dipple, K. M. (2005). Single-gene disorders: What role could moonlighting enzymes play? American Journal of Human Genetics, 76, 911–924.PubMedPubMedCentralCrossRefGoogle Scholar
  124. Stern, R., Shuster, S., Neudecker, B. A., & Formby, B. (2002). Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Experimental Cell Research, 276(1), 24–31.PubMedCrossRefGoogle Scholar
  125. Stringari, C., Donovan, P., & Gratton, E. (2012). Phasor FLIM metabolic mapping of stem cells and cancer cells in live tissues. In A. Periasamy, K. Konig, & P. T. C. So (Eds.), Multiphoton microscopy in the biomedical sciences Xii (Vol. 8226, Proceedings of SPIE).Google Scholar
  126. Stringari, C., Wang, H., Geyfman, M., Crosignani, V., Kumar, V., Takahashi, J. S., et al. (2015). In vivo single-cell detection of metabolic oscillations in stem cells. Cell Reports, 10(1), 1–7.PubMedCrossRefGoogle Scholar
  127. Subbaraman, N. (2011). Flawed arithmetic on drug development costs. Nature Biotechnology, 29(5), 381.PubMedCrossRefGoogle Scholar
  128. Sugimoto, M., Tahara, H., Ide, T., & Furuichi, Y. (2004). Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Research, 64, 3361–3364.PubMedCrossRefGoogle Scholar
  129. Tateno, C., Kawase, Y., Tobita, Y., Hamamura, S., Ohshita, H., Yokomichi, H., et al. (2015a). Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID Mice. Plos One, 10(11), e0142145.Google Scholar
  130. Tateno, C., Yamamoto, T., Utoh, R., Yamasaki, C., Ishida, Y., Myoken, Y., et al. (2015b). Chimeric mice with hepatocyte-humanized liver as an appropriate model to study human peroxisome proliferator-activated receptor-alpha. Toxicologic Pathology, 43(2), 233–248.PubMedCrossRefGoogle Scholar
  131. Tateno, C., Yoshizane, Y., Saito, N., Kataoka, M., Utoh, R., Yamasaki, C., et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. American Journal of Pathology, 165(3), 901–912.PubMedPubMedCentralCrossRefGoogle Scholar
  132. Telang, S., Lane, A. N., Nelson, K. K., Arumugam, S., & Chesney, J. A. (2007). The oncoprotein H-RasV12 increases mitochondrial metabolism. Molecular Cancer, 6, 77–91.PubMedPubMedCentralCrossRefGoogle Scholar
  133. Telang, S., Yalcin, A., Clem, A. L., Bucala, R., Lane, A. N., Eaton, J. W., et al. (2006). Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene, 25(55), 7225–7234.PubMedCrossRefGoogle Scholar
  134. Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., & Pitts, T. M. (2012). Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews Clinical Oncology, 9, 338–350.PubMedPubMedCentralCrossRefGoogle Scholar
  135. Thayanithy, V., Babatunde, V., Dickson, E. L., Wong, P., Oh, S., Ke, X., et al. (2014). Tumor exosomes induce tunneling nanotubes in lipid raft-enriched regions of human mesothelioma cells. Experimental Cell Research, 323(1), 178–188.PubMedPubMedCentralCrossRefGoogle Scholar
  136. Thelwall, P. E., Simpson, N. E., Rabbani, Z. N., Clark, M. D., Pourdeyhimi, R., Macdonald, J. M., et al. (2012). In vivo MR studies of glycine and glutathione metabolism in a rat mammary tumor. NMR in Biomedicine, 25, 271–278.PubMedCrossRefGoogle Scholar
  137. Thelwall, P. E., Yemin, A. Y., Gillian, T. L., Simpson, N. E., Kasibhatla, M. S., Rabbani, Z. N., et al. (2005). Noninvasive in vivo detection of glutathione metabolism in tumors. Cancer Research, 65(22), 10149–10153.PubMedCrossRefGoogle Scholar
  138. Uhlen, M., Fagerberg, L., Hallstrom, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., et al. (2015). Tissue-based map of the human proteome. Science, 347(6220), 394.CrossRefGoogle Scholar
  139. Unger, F. T., Bentz, S., Krüger, J., Rosenbrock, C., Schaller, J., Pursche, K., et al. (2015). Precision cut cancer tissue slices in anti-cancer drug testing. Journal of Molecular Pathophysiology, 4, 108–121.CrossRefGoogle Scholar
  140. Unger, F. T., Krueger, J., Schaller, J., Uhlig, P., Juhl, H., & David, K. A. (2014). Precision cut cancer tissue slices as a preclinical drug testing platform. European Journal of Cancer, 50, S166.CrossRefGoogle Scholar
  141. Uppal, A., & Gupta, P. K. (2003). Measurement of NADH concentration in normal and malignant human tissues from breast and oral cavity. Biotechnology and Applied Biochemistry, 37, 45–50.PubMedCrossRefGoogle Scholar
  142. Uriel, J. (1979). Retrodifferentiation and the fetal patterns of gene expression in cancer. Advances in Cancer Research, 29, 127–174.PubMedCrossRefGoogle Scholar
  143. Vaira, V., Fedele, G., Pyne, S., Fasoli, E., Zadra, G., Bailey, D., et al. (2010). Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proceedings of the National Academy of Sciences of the United States of America, 107(18), 8352–8356.PubMedPubMedCentralCrossRefGoogle Scholar
  144. Walenta, S., Schroeder, T., & Mueller-Klieser, W. (2004). Lactate in solid malignant tumors: Potential basis of a metabolic classification in clinical oncology. Current Medicinal Chemistry, 11(16), 2195–2204.PubMedCrossRefGoogle Scholar
  145. Warburg, O. (1923). Versuche an überlebendem Carcinomgewebe (Methoden). Biochem. Zeitschr., 142, 317–333.Google Scholar
  146. Wehrle, J. P., Ng, C. E., McGovern, K. A., Aiken, N. R., Shungu, D. C., Chance, E. M., et al. (2000). Metabolism of alternative substrates and the bioenergetic status of EMT6 tumor cell spheroids. NMR in Biomedicine, 13(6), 349–360.PubMedCrossRefGoogle Scholar
  147. Whittle, J. R., Lewis, M. T., Lindeman, G. J., & Visvader, J. E. (2015). Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Research, 17, 17.PubMedPubMedCentralCrossRefGoogle Scholar
  148. Wilding, J. L., & Bodmer, W. F. (2014). Cancer cell lines for drug discovery and development. Cancer Research, 74(9), 2377–2384.PubMedCrossRefGoogle Scholar
  149. Willyard, C. (2015). The boom in mini stomachs, brains, breasts, kidneys and more. Nature, 523, 520–522.PubMedCrossRefGoogle Scholar
  150. Wilson, D. M., & Kurhanewicz, J. (2014). Hyperpolarized C-13 MR for molecular imaging of prostate cancer. Journal of Nuclear Medicine, 55(10), 1567–1572.PubMedPubMedCentralCrossRefGoogle Scholar
  151. Winnike, J. H., Pediaditakis, P., Wolak, J. E., McClelland, R. W., Watkins, P. B., & Macdonald, J. M. (2012). Stable isotope resolved metabolomics of primary human hepatocytes reveals a stressed phenotype. Metabolomics, 8, 34–49.CrossRefGoogle Scholar
  152. Wolak, J., Rahimi-Keshari, K., Jeffries, R. E., Joy, M. P., Todd, A., Pediatikakis, P., et al. (2012). Noninvasive fluxomics in mammals by nuclear magnetic resonance spectroscopy. In T. W.-M. Fan, A. N. Lane, & R. M. Higashi (Eds.), The handbook of metabolomics (pp. 321–392). New York: Springer.CrossRefGoogle Scholar
  153. Wong, N. C., Bhadri, V. A., Maksimovic, J., Parkinson-Bates, M., Ng, J., Craig, J. M., et al. (2014). Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. BMC Genomics, 15, 416.PubMedPubMedCentralCrossRefGoogle Scholar
  154. Wysoczynski, M., & Ratajczak, M. Z. (2009). Lung cancer secreted microvesicles: Underappreciated modulators of microenvironment in expanding tumors. International Journal of Cancer, 125(7), 1595–1603.PubMedPubMedCentralCrossRefGoogle Scholar
  155. Xie, H., Hanai, J., Ren, J.-G., Kats, L., Burgess, K., Bhargava, P., et al. (2014). Targeting lactate dehydrogenase-A (LDH-A) inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor initiating cells. Cell Metabolism, 19, 795–809.PubMedPubMedCentralCrossRefGoogle Scholar
  156. Xu, D., & Peltz, G. (2016). Can humanized mice predict drug “behavior” in humans? Annual Review of Pharmacology and Toxicology, 56, 323–338.PubMedCrossRefGoogle Scholar
  157. Yoshizato, K., & Tateno, C. (2009). In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opinion on Drug Metabolism & Toxicology, 5(11), 1435–1446.CrossRefGoogle Scholar
  158. Yue, F., Cheng, Y., Breschi, A., Vierstra, J., Wu, W., Ryba, T., et al. (2014). A comparative encyclopedia of DNA elements in the mouse genome. Nature, 515, 355–364.PubMedPubMedCentralCrossRefGoogle Scholar
  159. Zachara, N. E., & Hart, G. W. (2004). O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochimica Et Biophysica Acta-General Subjects, 1673(1–2), 13–28.CrossRefGoogle Scholar
  160. Zamanakou, M., Germenis, A. E., & Karanikas, V. (2007). Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunology Letters, 111(2), 69–75.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of Toxicology and Cancer Biology, Center for Environmental and Systems Biochemistry (CESB)University of KentuckyLexingtonUSA

Personalised recommendations